Disubstituted 1, 2, 4-triazine compound

A method for treating heart failure, nephropathy, and sleep apnea syndrome, comprising administering a therapeutically effective amount of a compound of the following formula [I]:

• wherein
• RA is
• a group of the following formula (A-1):
• wherein ring A1 represents an aryl group which may be partially hydrogenated and may be substituted,
• wherein
• a substituent of an aryl group which may be partially hydrogenated and may be substituted represented by ring A1 in the above formula (A-1) is 1-3 groups selected independently from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxyalkyl group, an alkoxy group, and an alkylenedioxy group which may be substituted with 1-2 halogen atoms,
• an aryl moiety in the aryl group which may be partially hydrogenated and may be substituted is 6- to 10-membered monocyclic or bicyclic aryl,
• RB is
• a group of the following formula (B-4):
• wherein Xa represents CR3a or N,
• (i) when Xa represents CR3a,
• Xb represents CHR3b, Xc represents O or NR4c,
• Xb represents O, Xc represents NR4c, or
• Xb represents NR4b, Xa represents O, NR4c, or CHR3c,
• (ii) when Xa represents N,
• Xb represents CHR3b or C(═O), Xc represents NR4c, or
• Xb represents NR4b, Xc represents CHR3c;
• R3a represents a hydrogen atom, a hydroxyl group, an alkyl group, or an amino group,
• each of R3b and R3c represents a group selected independently from the group consisting of a hydrogen atom, a hydroxyl group, and an alkyl group,
• each of R3b and R4c represents a group selected independently from the group consisting of a hydrogen atom, an alkyl group, and a cycloalkyl group;
• RB6 represents a hydrogen atom or an alkyl group;
• RB7 represents
• (i) a cycloalkyl group which may be substituted,
• (ii) an aliphatic heterocyclic group which may be substituted,
• (iii) a heteroaryl group which may be partially hydrogenated and may be substituted, or
• when Xc represents NR4c, RB7 and R4c are bound to each other at their terminus to form an aliphatic heterocyclic group, which may be substituted with an alkyl group which may be substituted, together with a nitrogen atom to which they are bound,
• wherein
• a substituent of (i) the cycloalkyl group which may be substituted, (ii) the aliphatic heterocyclic group which may be substituted, and (iii) the heteroaryl group which may be partially hydrogenated and may be substituted represented by RB7 is 1-4 groups selected independently from the group consisting of a halogen atom;
• a hydroxyl group;
• an oxo group;
• an alkyl group which may be substituted with 1-3 groups selected independently from the group consisting of a hydroxyl group, an alkoxy group, an alkylsulfonyl group, an amino group which may be substituted with 1-2 groups selected independently from the group consisting of an alkoxycarbonyl group and an alkylsulfonyl group, a carbamoyl group which may be substituted with 1-2 alkyl groups, a cycloalkyl group which may be substituted with a hydroxyl group, an aliphatic heterocyclic carbonyl group, and a heteroaryl group which may be substituted with an alkyl group and may be partially hydrogenated;
• a cycloalkyl group which may be substituted with 1-2 groups selected independently from the group consisting of a hydroxyl group and an alkylsulfonyl group;
• an aryl group;
• a heteroaryl group which may be partially hydrogenated;
• an alkanoyl group which may be substituted with 1-3 groups selected independently from the group consisting of a halogen atom and a hydroxyl group;
• a cycloalkylcarbonyl group which may be substituted with a hydroxyl group;
• an aliphatic heterocyclic carbonyl group which may be substituted with an alkyl group;
• an amino group which may be substituted with 1-2 groups selected independently from the group consisting of an alkyl group which may be substituted with an alkylsulfonyl group, an alkanoyl group, and an alkoxycarbonyl group;
• a carbamoyl group which may be substituted with 1-2 alkyl groups;
• an alkylsulfonyl group;
• an alkoxy group which may be substituted with a carbamoyl group which may be substituted with 1-2 alkyl groups;
• and an aliphatic heterocyclic group which may be substituted with 1-3 groups selected independently from the group consisting of a hydroxyl group, an oxo group, an alkyl group, an alkanoyl group, and an alkylsulfonyl group, or
• when RB7 is (i) a cycloalkyl group which may be substituted, or (ii) an aliphatic heterocyclic group which may be substituted, two substituents on the same ring-constituting carbon atom may be bound to each other at the terminus thereof to form an alkylene group which may be substituted (wherein a substituent of the alkylene group is an oxo group or an alkyl group, and the alkylene group may contain 1-3 heteroatoms selected independently from a sulfur atom, an oxygen atom, and a nitrogen atom),
• in RB7, aryl is 6- to 10-membered monocyclic or bicyclic aryl, heteroaryl is 5- to 10-membered monocyclic or bicyclic heteroaryl which contains 1-4 heteroatoms selected independently from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom, an aliphatic heterocyclic ring is a 4- to 9-membered aliphatic heterocyclic ring which contains 1-2 heteroatoms selected independently from the group consisting of an oxygen atom and a nitrogen atom, or
• when Xc is NR4c, and RB7 and R4c are bound to each other at their terminus to form an aliphatic heterocyclic group which may be substituted with an alkyl group which may be substituted, together with a nitrogen atom to which they are bound, a substituent of the alkyl group which may be substituted is a hydroxyl group, and the aliphatic heterocyclic group is a 4-to 9-membered aliphatic heterocyclic ring which may further contain 1 heteroatom selected independently from the group consisting of a sulfur atom, an oxygen atom and a nitrogen atom other than the nitrogen atom to which RB7 and R4c are bound,
• or a pharmaceutically acceptable salt thereof to a patient in need thereof.